Clinical Trials Logo

Filariasis clinical trials

View clinical trials related to Filariasis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04410406 Active, not recruiting - Clinical trials for Lymphatic Filariasis

Moxidectin for LF, Cote d'Ivoire (DOLF)

Start date: August 20, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).

NCT ID: NCT04258670 Active, not recruiting - Clinical trials for Lymphatic Filariasis

Spontaneous Antigenemia in Loiasis

Start date: January 23, 2020
Phase:
Study type: Observational [Patient Registry]

This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood. This study will define the cross-reactive antigen profile of persons with spontaneous loiasis antigenemia, and determine whether it varies with time.

NCT ID: NCT03014167 Active, not recruiting - Helminthiasis Clinical Trials

Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

Start date: October 4, 2017
Phase: Phase 3
Study type: Interventional

Over 1.5 billion people are infected with soil-transmitted helminths (STH). Global STH guidelines recommend MDA (mass drug administration) of albendazole or mebendazole to targeted populations, including pre-school age children and school-age children. However mathematical models suggests that current MDA strategies are not sufficient for interrupting disease transmission in most areas. Meanwhile many lymphatic filariasis (LF) programs have successfully treated entire populations with albendazole (in combination with ivermectin or diethylcarbamazine) and are transitioning to a state of post-MDA surveillance. This project will conduct a series of community-based cluster randomized trials in India, Malawi, and Benin to determine if maintaining three years of MDA with albendazole to entire communities following the cessation of LF programs can interrupt STH transmission in focal geographic areas. Additionally, this study aims to compare the efficacy of community-wide MDA versus targeted MDA of children in interrupting the transmission of STH. Nested implementation science research will be used to optimize the intervention, identify contextual factors influencing trial efficacy, and evaluate the feasibility of sustaining and scaling community-wide MDA for STH. These data will provide evidence necessary to inform future guidelines, policies, and operational plans as country partners engage in intensified approaches to eliminate these disabling diseases.